Still time to submit an abstract for the EACPT Congress in Sweden: 29th June to 2nd July 2019

Stockholm

The next EACPT Congress will be held from 29th June to 2nd July in 2019 in Stockholm as a partnership between the EACPT and the Swedish Society for Pharmacology, Clinical Pharmacology and Therapeutics.

The Congress will address Tomorrow's Healthcare Challenges and will be held at the City Conference Centre - 5 minutes from Stockholm Central Station.

Abstract closing date extended to 14th March.

Register online

The Congress Reception on the evening of Saturday 29th June, will be held at Stockholm City Hall, the venue of the Nobel Prize banquet.

The Keynote Opening Lecture will be given by the President at the Karolinska Institute, Professor Ole Petter Ottersen, on global health and clinical pharmacology.

Around 60 invited speakers are expected from throughout Europe and beyond. Congress keynote lectures, sessions and themes will include:

• Advanced therapies
• Chronic disease
• Clinical pharmacologists versus computers
• Closing the money gap  
• Drug regulation in the 2020's
• EACPT meets Asian Societies      
• EPHAR-EACPT joint symposium on personalised medicine
• Ethics in clinical research
• Global Health
• How to become a clinical pharmacologist
• How to measure drug exposure
• How to measure drug use
• How to perform a health economic study
• Interprofessional exchange for better drug treatment
• Misuse of medicines
• Patient empowerment
• Preparing tomorrow's prescribers
• Prescribing and deprescribing
• Targeting small populations  
• The critically ill patient
• Treating ageing populations 
• Treating cancer
• Treating children

Major awards to be presented at the Stockholm Congress include the EACPT Lifetime Achievement Award and the biennial EACPT Scientific Award for best publication on a clinical pharmacology or therapeutic theme.

Opportunities for EACPT Associate Members include
* discounted registration fees for EACPT meetings
* networking with colleagues worldwide through the global EACPT network of Associate Members
* active involvement in EACPT Working Parties and other activities 

Find out how to become an Associate Member of the EACPT 

Future EACPT Congresses will be held in:
- 2021 Athens
- 2023 Rotterdam

The EACPT was founded in 1993 and now includes as members all national organisations for clinical pharmacology in Europe, as well as organisations from further afield internationally. The EACPT aims to provide educational and scientific support for the more than 4000 individual professionals interested in clinical pharmacology and therapeutics throughout the European region, with its congresses attended by a global audience. The EACPT also advises policy makers on how the specialty can contribute to human health and wealth.

Updates on the EACPT from the UK

The EACPT Executive Committee is meeting in early September 2018 in Birmingham in the UK West Midlands to plan for future activities. This coincides with the latest EACPT Focus meeting: Innovations in CPT Education - which is being held at the University of Birmingham from 7-8 September 2018. Delegates for the Focus meeting are expected from a wide range of countries, including Finland, Germany, Ireland, The Netherlands, Sweden, Switzerland, Lithuania, Poland, Italy, Spain, Romania, Malta and the UK.

EACPT EC in Birmingham

Key matters for discussion by the EACPT EC included:

1. Future EACPT Congresses - the next is due to be held from 29th June to 2nd July in 2019 in Stockholm as a partnership between the EACPT and the Swedish Society for Pharmacology, Clinical Pharmacology and Therapeutics. The Congress will address Tomorrow's Healthcare Challenges and will be held at the City Conference Centre - 5 minutes from Stockholm Central Station.
The Keynote Opening Lecture will be given by the President at the Karolinska Institute, Professor Ole Petter Ottersen, on global health and clinical pharmacology.

Congress sessions and themes will include:

• Advanced therapies
• Chronic disease
• Clinical pharmacologists versus computers
• Closing the money gap  
• Drug regulation in the 2020's
• EACPT meets Asian Societies      
• EPHAR-EACPT joint symposium on personalised medicine
• Ethics in clinical research
• Global Health
• How to become a clinical pharmacologist
• How to measure drug exposure
• How to measure drug use
• How to perform a health economic study
• Interprofessional exchange for better drug treatment
• Misuse of medicines
• Patient empowerment
• Preparing tomorrow's prescribers
• Prescribing and deprescribing
• Targeting small populations  
• The critically ill patient
• Treating ageing populations 
• Treating cancer
• Treating children

2. New EACPT Awards for Best Scientific Paper in the previous 12 months on a clinical pharmacology or therapeutics theme. Authors may be from any discipline and do not have to be members of the EACPT. These awards will be launched in September 2018 and awarded initially every 2 months (6 times a year) from November 2018. 

Award winners will receive a free one year Individual Associate Membership (IAM) of the EACPT. Winners who are already EACPT IAMs will receive a 100€ prize. Papers which receive an EACPT Scientific Paper Award will be eligible to be considered for the biennial EACPT Scientific Award.

3. EACPT working groups on Education, Research, Young Professionals, and Regulation and Ethics.

4. New EACPT web series on Meet the Clinical Pharmacologists

5. Opportunities from links with international organisations such as the European Medicines Agency, IUPHAR, EPHAR and UEM|

6. Opportunities for Individual Associate Members including:
* discounted registration fees for EACPT meetings
* networking with colleagues worldwide through the global EACPT network of Associate Members
* active involvement in EACPT Working Parties and other activities  

Find out how to become an Associate Member of the EACPT  

The EACPT Executive Committee meets 6 monthly, with regular additional discussions by teleconference on key EACPT strategy and activities.

Future EACPT Congresses will be held in:
- 2019 Stockholm
- 2021 Athens
- 2023 Rotterdam

The EACPT was founded in 1993 - 25 years ago - and now includes as members all national organisations for clinical pharmacology in Europe, as well as organisations from further afield internationally. The EACPT aims to provide educational and scientific support for the more than 4000 individual professionals interested in clinical pharmacology and therapeutics throughout the European region, with its congresses attended by a global audience. The EACPT also advises policy makers on how the specialty can contribute to human health and wealth.

Developing a Common Health Data Model for Europe

The European Medicines Agency has been holding a 2 day international workshop in London [11th -12th December 2017] to define  opportunities and challenges for a common health data model in Europe. The expected outcome of the workshop was agreeing guiding principles for the development of such a Common Data Model (CDM) in Europe, including key criteria for validation in the context of regulatory decision-making.

See more about the workshop
 

A common data model could help harmonise healthcare data across multiple data sets and provide a mechanism to conduct pan-European studies in a timely manner to address regulatory questions. At the same time, applying a common model to European data has multiple challenges. The meeting brought together regulators with academia, data holders and the pharmaceutical industry.

Sessions included talks from experts from North America and the European region discussing lessons learned and current challenges in very large current clinical data resources, regulatory verification and related issues. Common data model case studies  included Sentinel – the Harvard-based FDA system for accessing patient data from health data partners across the USA and CNODES (the Canadian Network for Operational Drug Effect Studies) which can access data on 100 million patients – a similar scale to Sentinel.

The U.S. Food and Drug Administration's (FDA) Sentinel Initiative uses a common health data model to improve the FDA’s ability to identify safety issues for medical products. Sentinel actively surveys pre-existing electronic healthcare data from multiple sources.

Themes at the workshop included ensuring the relevance of CDMs to health policy, keeping timelines short, inter-operability, consent and related ethical issues, and careful internal and external validation of clinical definitions, data, software and analytical models.

From the perspective of health professionals, policy makers, regulators and the public, key future questions include whether clinical outcomes from common data models will be generalisable or only relevant to specific sub-populations based on geography, genetics, demographics and/or complex co-morbidity.  In the era of precision medicine there is the clear need is to avoid “right” answers from the wrong clinical populations and “wrong” answers from the right populations.
Further key points to consider include the cost of CDMs and who should pay; and whether updating existing databases will be sufficient or will new, more robust databases be needed.

 Future EACPT Congresses will be held in:
- 2019 Stockholm
- 2021 Athens
- 2023 Rotterdam

The EACPT was founded in 1993 - 24 years ago - and now includes as members all major national organisations for clinical pharmacology in Europe, as well as organisations from further afield internationally. The EACPT aims to provide educational and scientific support for the more than 4000 individual professionals interested in clinical pharmacology and therapeutics throughout the European region, with its congresses attended by a global audience. The EACPT also advises policy makers on how the specialty can contribute to human health and wealth.

Clinical Therapeutics, the Official Journal of EACPT

Join EACPT to access new video library of talks on medicines from 2015 Madrid Congress

The EACPT has just released a library of almost 60 videos of talks from the 2015 Madrid

Plaza Major, Madrid

Congress. These videos are now available for EACPT members within the members’ pages of the EACPT website. See below for the list of speakers and their topics, ranging from Alzheimer's to cancer, treating children, regulating medicines, the patient's voice, medicines for low resource global settings, biosimilars, and patient safety.

Access to the videos is free for Individual Associate members of the EACPT.

To view the videos as an existing EACPT member, open the ‘Publications’ drop down menu on the members' pages of the website.



Click here to apply online for EACPT membership.

Anyone from anywhere in the world with a professional interest in clinical pharmacology and/or therapeutics can now join the EACPT as an Individual Associate member.

Membership benefits include:

• Access to videos of talks from EACPT Meetings
• Discounted registration fees for EACPT meetings
• Online access to the Official EACPT Journal - Clinical Therapeutics
• Access to the EACPT’s worldwide network of Individual Associate Members
• Active involvement in EACPT 

If you are an existing Individual Associate member of the EACPT and have any query regarding your membership login details for the website, please contact eacptmembership@kenes.com.

This new portfolio of videos enriches the existing library of videos of talks available on the EACPT members’ website from the EACPT Cardiovascular focus meeting held in Nijmegen in 2014.

Main topics and speakers

Biosimilar medicinal products. How to enhance healthcare systems sustainability without compromising clinical practice.
Martina Weise (Germany), Cristina Avendaño-Solá (Spain), Aleksandra Grozdanova (Macedonia)

Debate on therapeutic innovation: Does industry research meet the needs of society?
Xavier Carné (Spain) vs. Ruth Diazaraque (United Kingdom)

Debate on pharmacoepidemiology databases
Miriam CJM Sturkenboom (The Netherlands) vs. Tom MacDonald (United Kingdom)

Current challenges in cancer treatment.
Luis Paz Ares (Spain)

Novel insights in ADME
Janne Backman (Finland), Amin Rostami (United Kingdom)

Handling medicines in special populations

- Renal function in older people: Emmanuelle Vidal-Petiot (France)

- Rational pharmacotherapy in children: Imti Choonara (United Kingdom)

- Appropriate prescribing in older patients: Beatriz Montero (Spain)

Medicines and Global Health
Nicola Magrini (WHO, Switzerland), Lembit Rägo (WHO, Switzerland). Raj Long (Bill and Melinda Gates Foundation, UK), Antoni Plasencia (Spain)

Drug development for regulatory approval and reimbursement decisions
Beate Wieseler (Germany), Pierre Demolis (France), Bruno Flamion (Belgium)

Key factors for successful research in Europe
Rafael de Andrés Medina (Spain), Jacques Demotes (France), Javier Urzay (Spain)

Implementation of Pharmacogenetics and Personalised Medicine in Clinical Practice
Raul A. Kiivet (Estonia)

Interventions that improve the use of medicines in clinical practice
Tormod K Bjånes (Norway), Romaldas Maciulaitis (Lithuania), Milan Grundmann (Czech Republic), Espen Jimenez-Solem (Denmark), Carl-Olav Stiller (Sweden), Mikkel Christensen (Denmark), Cornelis Kramers (Netherlands), Kirstine Moll Harboe (Denmark), Cándido Hernández-López (Spain)

Biomarkers in Alzheimer clinical research
Claudio Babiloni (Italy)

Medicines regulation, access to medicines and the patient’s voice
Denis Pouchain (France), Nick Meade (United Kingdom), Toni Gilabert (Spain)

Heterogeneity in drug response
Juan Tamargo (Spain), Caridad Pontes (Spain), Eduard Vieta (Spain)

Immunopharmacology of TNF-alpha: disease-transcending therapies
Roman Fischer (Germany), Johannan Brandse (The Netherlands), Marie-Christophe Boissier (France)

Pharmacovigilance - Risk communication to health professionals and citizens
Barbara Rath (Germany), Almath Spooner (Ireland), Frederic Bouder (Netherlands)

Drug Information and Decision Support Systems to support rational drug treatment
Robert Vander Stichele (Belgium), Ylva Böttiger (Sweden)

Hepatitis B reactivation. How to manage the risk?
José Luis Calleja (Spain)

Progressive multifocal leukoencephalopathy. Risk perception in the therapeutic context
Brigitte Keller-Stanislawski (Germany)

Registries for long-term risks
Ignacio García Doval (Spain)

Drug Induced Liver Injury
Raúl Andrade (Spain), Paul Watkins (USA), Michael Merz (Switzerland), Herve Le Louët (France)

Training on medicines regulation
Arantxa Sancho, Martina Weise, Jorge Camarero, Antonio Gomez-Oute